SCHEMBL30278482

SCHEMBL30278482

O=[N+]([O-])n1c(=S)oc2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.42
KMT2A Q03164 7/20 0.42
MAPT P10636 4/20 0.42
HTT P42858 4/20 0.42
LMNA P02545 3/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 3/20 0.42
MDM2 Q00987 2/20 0.42
PAX8 Q06710 1/20 0.42
HPGD P15428 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPK1 P28482 2/20 0.37
USP2 O75604 1/20 0.37
TSHR P16473 1/20 0.37
MITF O75030 1/20 0.37
MEN1 O00255 5/20 0.35
POLB P06746 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NPSR1 Q6W5P4 2/20 0.34
DUSP3 P51452 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17156224 0.68 P2RX4 (0.56) ALDH1A1KMT2AMAPTHTTLMNA
SCHEMBL17156131 0.68 ALDH1A1 (0.44) ALDH1A1KMT2AMAPTHTTLMNA
SCHEMBL5252911 0.67 ALDH1A1 (0.47) ALDH1A1KMT2AMAPTHTTLMNA
SCHEMBL21554356 0.67 ALDH1A1 (0.44) ALDH1A1KMT2AMAPTHTTLMNA
SCHEMBL1653137 0.66 MAPT (0.40) ALDH1A1KMT2AMAPTHTTLMNA
SCHEMBL3557147 0.66 MAPT (0.46) ALDH1A1KMT2AMAPTHTTLMNA
SCHEMBL21712537 0.64 ALDH1A1 (0.63) ALDH1A1KMT2AMAPTHTTLMNA
SCHEMBL8550634 0.64 ALDH1A1 (0.49) ALDH1A1KMT2AMAPTHTTLMNA
SCHEMBL4370885 0.63 ALDH1A1 (0.44) ALDH1A1KMT2AMAPTHTTLMNA
SCHEMBL11876810 0.63 HSD17B10 (0.38) ALDH1A1KMT2AMAPTHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376452-A1 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof ENANTA PHARM INC (US) 2025-12-11 US disclosed
US-12384753-B2 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2025-08-12 US disclosed
EP-4387603-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF Enanta Pharmaceuticals, Inc. (US) 2024-06-26 EP disclosed
CN-118103038-A 17 Beta-hydroxysteroid dehydrogenase 13 inhibitors and methods of use thereof 英安塔制药有限公司 2024-05-28 CN disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 ALDH1A1 125/4885KMT2A 3702/4885MAPT 3642/4885
US-20250376452-A1 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof HSD17B1, HSD17B13, HSD17B3 ALDH1A1 125/4885KMT2A 3702/4885MAPT 3642/4885
US-12384753-B2 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof HSD17B1, HSD17B13, HSD17B3 ALDH1A1 125/4885KMT2A 3702/4885MAPT 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.